MALVERN, PA — Ocugen Inc. (Nasdaq: OCGN) has completed enrollment and dosing in its Phase 2/3 clinical trial evaluating a ...

Ocugen, Inc. announced that the U.S. FDA has granted Rare Pediatric Disease Designation to its treatment OCU410ST for ABCA4-associated retinopathies, including Stargardt disease. This follows prior ...

Ocugen completes GARDian3 enrollment early as OCU410ST gene therapy targets Stargardt disease with no approved treatments.

GARDian3 trial enrollment and dosing completed (N=63) in less than nine monthsTopline results expected in 2Q27 with BLA to follow by ...

Please provide your email address to receive an email when new articles are posted on . The FDA granted rare pediatric disease designation for OCU410ST, a gene therapy designed to treat ...

Please provide your email address to receive an email when new articles are posted on . VG801 is a dual-AAV gene therapy in development for the treatment of Stargardt disease. The therapy is under ...

The ongoing GARDian3 study is designed to assess whether a single subretinal administration of OCU410ST can slow structural ...

MALVERN, Pa., May 27, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (OCGN) (Ocugen or the Company), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the United ...

AAVB-039 addresses the root cause of the disease, benefitting patients with any ABCA4 mutation AAVB-039 is currently being assessed in the CELESTE interventional clinical trial and we continue ...

VG801 shows encouraging preliminary efficacy in the ongoing Phase 1/2 trial, with consistent functional improvements in best-corrected visual acuity (BCVA) and Virtual Reality Visual Test (VRVT), ...

Three months after dosing the first patient with its dual vector gene therapy, Splicebio SL has closed a $135 million series B to fund the phase I/II trial of SB-007 in the treatment of Stargardt’s ...